Pneumonia is a lung infection which occurs in one or both the lungs caused by bacteria, fungi or viruses. Bacterial pneumonia is the common form occurring in adults. Pneumonia results in inflammation in the air sacs (known as alveoli) of the lungs, that results in filling the alveoli with fluid, so causing breathing problems. This disease is common in young children, older adults are at high risk of severe pneumococcal infections and even death. Growing prevalence of pneumonia across the globe, increasing government focus on immunization programs for pneumonia, as well as introduction of novel pneumococcal vaccines such as PCV10 are the factors that drive growth of global Pneumonia Vaccine market. Pneumonia Vaccine such as Pneumococcal Conjugate Vaccine (PCV13), and Pneumococcal Polysaccharide Vaccine (PPSV23) are used for treatment of Pneumonia.This growth is primarily driven by Rising Government Involvement in Design & Implementation of Comprehensive Vaccination Programs
|Avail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility
The Pharmaceuticals sector in the North America region has been increasing at a sustainable rate and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as Pfizer Inc. (United States), GlaxoSmithKline plc. (United Kingdom), Merck & Co., Inc. (United States), Sanofi Pasteur (France), Serum Institute of India Private Limited (India), Astellas Pharma Inc. (Japan), CSL Limited (Australia), Emergent Biosolutions, Inc. (United States), Biological E limited (India) and Panacea Drugs Pvt. Ltd. (India), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.
Regulatory Insights:“In United States, The Center for Disease Control and Prevention (CDC), a leading national public health institute recommends yearly influenza vaccination for every person 6 months and older. Immunizing health care workers decreases the risk of viral pneumonia among their patients. CDC recommends pneumococcal vaccination for all children younger than 2 years old and all adults 65 years or older. In certain situations, other children and adults should also get pneumococcal vaccines.”
Market Growth Drivers:Rising Government Involvement in Design & Implementation of Comprehensive Vaccination Programs, Increasing Prevalence of Pneumonia Infection among People and Growing Awareness Regarding Pneumonia Vaccine
Challenges:Insufficient Access to Vaccines
Restraints:High Cost of Vaccine Development
Opportunities:High Growth Prospects in Emerging Markets and Advancement of Protein-Based Combination Pneumococcal Vaccines
AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mainly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the market's growth. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.
Data Sources of Pneumonia Vaccine Market Study
Primary Collection: InMail, LinkedIn Groups, Survey Monkey, Google, and Other professional Forums are some of the mediums utilized to gather primary data through key industry participants and appointees, subject-matter experts, C-level executives of Pneumonia Vaccine Industry, among others including independent industry consultants, experts, to obtain and verify critical qualitative commentary and opinion and quantitative statistics, to assess future market prospects.
The primary interviews and data collected as per the below protocols:
By Designation: C-Level, D-Level, Others
By Company Type: Tier 1, Tier 2, Tier 3
Secondary Data Sources such as Annual reports, Press releases, Analyst meetings, Conference calls, Investor presentations, Management statements, and SEC filings of Pneumonia Vaccine players along with Regulatory Sites, Association, World bank, etc were used as sources secondary set of data.
Customization in the ReportAMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis
Against this Challenging Backdrop, Pneumonia Vaccine Study Sheds Light on The Pneumonia Vaccine Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Pneumonia Vaccine industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
Where Pneumonia Vaccine industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.